Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_assertion type Assertion NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_head.
- NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_assertion description "[The discovery of the JAK2V617F mutation followed by the discovery of other genetic abnormalities allowed important progress in the understanding of the pathogenesis and management of myeloproliferative neoplasms (MPN)s. Classical Breakpoint cluster region-Abelson (BCR-ABL)-negative neoplasms include 3 main disorders: essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_provenance.
- NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_assertion evidence source_evidence_literature NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_provenance.
- NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_assertion SIO_000772 25486952 NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_provenance.
- NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_assertion wasDerivedFrom befree-2016 NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_provenance.
- NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_assertion wasGeneratedBy ECO_0000203 NP1246142.RARnk4JCz5Gk2k_eoZZxHPmRcfEoIdUH0c0OlmZtPUa50130_provenance.